Table 2 Summary of meta-analysis on cardiovascular events with ARSIs.

From: Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis

  

Data summary of included studies

Pooled RR (95% CI), p-value

Cochran’s Q test

Cardiac disorder

Any grade

5 studies

5786 patients

1.39 (1.10–2.22), p < 0.01

p = 0.06

Grade ≥3

7 studies

6546 patients

1.74 (1.13–2.68), p = 0.01

p = 0.06

Heart failure

Any grade

9 studies

11,255 patients

1.60 (0.96–2.67), p = 0.07

p > 0.9

Grade ≥3

7 studies

8988 patients

2.49 (1.05–5.91), p = 0.04

p > 0.9

IHD

Any grade

6 studies

7215 patients

2.36 (1.53–3.65), p < 0.001

p = 0.03

Grade ≥3

5 studies

5820 patients

2.04 (0.91–4.62), p = 0.09

p < 0.01

AF

Any grade

9 studies

9412 patients

1.41 (1.02–1.94), p = 0.04

p = 0.5

Grade ≥3

7 studies

7028 patients

2.15 (1.14–4.07), p = 0.02

p > 0.9

Hypertension

Any grade

19 studies

17,180 patients

1.68 (1.38–2.05), p < 0.001

p < 0.001

Grade ≥3

16 studies

15,868 patients

2.06 (1.67–2.54), p < 0.01

p = 0.1

  1. ARSI androgen receptor signaling inhibitor, RR risk ratio, CI Confidence Interval, IHD Ischemic heart disease, AF atrial fibrillation
Back to article page